Cargando…

Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data

BACKGROUND: Spasticity after stroke has been internationally recognized as an important health problem causing impairment of mobility, deformity, and pain. The aim of this study was to assess the frequency of first-ever and recurrent stroke and of subsequent spastic and flaccid paresis. Factors infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Egen-Lappe, Veronika, Köster, Ingrid, Schubert, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601044/
https://www.ncbi.nlm.nih.gov/pubmed/23516125
http://dx.doi.org/10.2147/IJGM.S36030
_version_ 1782475706431700992
author Egen-Lappe, Veronika
Köster, Ingrid
Schubert, Ingrid
author_facet Egen-Lappe, Veronika
Köster, Ingrid
Schubert, Ingrid
author_sort Egen-Lappe, Veronika
collection PubMed
description BACKGROUND: Spasticity after stroke has been internationally recognized as an important health problem causing impairment of mobility, deformity, and pain. The aim of this study was to assess the frequency of first-ever and recurrent stroke and of subsequent spastic and flaccid paresis. Factors influencing the development of spasticity were analyzed. A further major aim was to provide a “real-life” assessment of the treatment of spasticity in Germany and to discuss this in view of the treatment recommended by German and international clinical guidelines. METHODS: The database used in this study comprised a cohort of 242,090 insurants from a large statutory health insurance fund in the federal state of Hesse, Germany. A first hospital discharge diagnosis in 2009 with any of the International Classification of Diseases, Tenth Revision (ICD-10) codes I60–I64 was used to identify patients with acute stroke (hemorrhage and ischemic). These patients were followed up six months after stroke to monitor whether they developed spastic or flaccid paresis (hospital or ambulatory care diagnoses ICD-10 code G81–G83 [excluding G82.6/G83.4/G83.8]). For patients with spastic paresis after stroke the spasticity treatment was analyzed for a six-month period (physiotherapy, oral muscle relaxants, intrathecal baclofen, and botulinum toxin). RESULTS: Standardized to the population of Germany, 3.7 per 1000 persons suffered a stroke in 2009 (raw 5.2/1000). Of all surviving patients, 10.2% developed spasticity within 6 months. Cox regression revealed no significant influence of patient age, gender, morbidity (diabetes, hypertensive diseases, ischemic heart diseases) or type of stroke on development of spasticity. 97% of surviving patients with spasticity received physiotherapy (inpatient care 89%, ambulatory care 48%). Oral muscle relaxants were prescribed to 13% of the patients. No patient received intrathecal baclofen or botulinum toxin. CONCLUSION: Claims data enabled analysis of the occurrence of stroke and post-stroke spasticity. These data provide insight into real-life treatment for spasticity in Germany. The proportion of patients who receive physiotherapy, which is the international guideline-recommended basic therapy after transition into ambulatory care, can be improved on. Botulinum toxin as an international guideline-based treatment option for focal spasticity has not been implemented in practice in Germany as yet.
format Online
Article
Text
id pubmed-3601044
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36010442013-03-19 Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data Egen-Lappe, Veronika Köster, Ingrid Schubert, Ingrid Int J Gen Med Original Research BACKGROUND: Spasticity after stroke has been internationally recognized as an important health problem causing impairment of mobility, deformity, and pain. The aim of this study was to assess the frequency of first-ever and recurrent stroke and of subsequent spastic and flaccid paresis. Factors influencing the development of spasticity were analyzed. A further major aim was to provide a “real-life” assessment of the treatment of spasticity in Germany and to discuss this in view of the treatment recommended by German and international clinical guidelines. METHODS: The database used in this study comprised a cohort of 242,090 insurants from a large statutory health insurance fund in the federal state of Hesse, Germany. A first hospital discharge diagnosis in 2009 with any of the International Classification of Diseases, Tenth Revision (ICD-10) codes I60–I64 was used to identify patients with acute stroke (hemorrhage and ischemic). These patients were followed up six months after stroke to monitor whether they developed spastic or flaccid paresis (hospital or ambulatory care diagnoses ICD-10 code G81–G83 [excluding G82.6/G83.4/G83.8]). For patients with spastic paresis after stroke the spasticity treatment was analyzed for a six-month period (physiotherapy, oral muscle relaxants, intrathecal baclofen, and botulinum toxin). RESULTS: Standardized to the population of Germany, 3.7 per 1000 persons suffered a stroke in 2009 (raw 5.2/1000). Of all surviving patients, 10.2% developed spasticity within 6 months. Cox regression revealed no significant influence of patient age, gender, morbidity (diabetes, hypertensive diseases, ischemic heart diseases) or type of stroke on development of spasticity. 97% of surviving patients with spasticity received physiotherapy (inpatient care 89%, ambulatory care 48%). Oral muscle relaxants were prescribed to 13% of the patients. No patient received intrathecal baclofen or botulinum toxin. CONCLUSION: Claims data enabled analysis of the occurrence of stroke and post-stroke spasticity. These data provide insight into real-life treatment for spasticity in Germany. The proportion of patients who receive physiotherapy, which is the international guideline-recommended basic therapy after transition into ambulatory care, can be improved on. Botulinum toxin as an international guideline-based treatment option for focal spasticity has not been implemented in practice in Germany as yet. Dove Medical Press 2013-03-13 /pmc/articles/PMC3601044/ /pubmed/23516125 http://dx.doi.org/10.2147/IJGM.S36030 Text en © 2013 Egen-Lappe et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Egen-Lappe, Veronika
Köster, Ingrid
Schubert, Ingrid
Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title_full Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title_fullStr Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title_full_unstemmed Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title_short Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data
title_sort incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on german statutory health insurance data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601044/
https://www.ncbi.nlm.nih.gov/pubmed/23516125
http://dx.doi.org/10.2147/IJGM.S36030
work_keys_str_mv AT egenlappeveronika incidenceestimateandguidelineorientedtreatmentforpoststrokespasticityananalysisbasedongermanstatutoryhealthinsurancedata
AT kosteringrid incidenceestimateandguidelineorientedtreatmentforpoststrokespasticityananalysisbasedongermanstatutoryhealthinsurancedata
AT schubertingrid incidenceestimateandguidelineorientedtreatmentforpoststrokespasticityananalysisbasedongermanstatutoryhealthinsurancedata